Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms (LUTS)

This study has been completed.
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
The Methodist Hospital System Identifier:
First received: October 20, 2011
Last updated: July 16, 2014
Last verified: July 2014
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2014
  Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)